Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $67.4M | $0.00 |
| Revenue growth | — | — | — | — | — | — | -100.0% |
| Operating income | -$46.8M | -$119M | -$217M | -$227M | -$300M | -$191M | -$153M |
| Operating margin | — | — | — | — | — | -283.6% | — |
| Net income | -$45.7M | -$118M | -$159M | -$237M | -$292M | -$166M | -$137M |
| Net margin | — | — | — | — | — | -246.0% | — |
| EPS (diluted) | -$8.16 | -$4.19 | -$3.72 | -$4.48 | -$4.47 | -$2.33 | -$1.91 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.1M | -$86.8M | -$154M | -$164M | -$208M | -$171M | -$125M |
| Capital expenditures | $352K | $758K | $6.11M | $2.55M | $583K | $221K | $0.00 |
| Free cash flow | -$39.5M | -$87.6M | -$160M | -$166M | -$208M | -$171M | -$125M |
| Share buybacks | — | — | — | — | $0.00 | $0.00 | $9.98M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $67.2M | $55.0M | $59.7M | $43.1M | $28.0M | $33.9M | $36.0M |
| Total assets | $87.5M | $366M | $455M | $539M | $552M | $430M | $289M |
| Total liabilities | $19.1M | $32.2M | $90.0M | $105M | $114M | $93.2M | $72.8M |
| Shareholders' equity | -$73.3M | $333M | $364M | $434M | $437M | $337M | $216M |
| Retained earnings | -$83.0M | -$201M | -$360M | -$596M | -$889M | -$1.05B | -$1.19B |
| Shares (wtd avg diluted) | 5.60M | 28.1M | 42.7M | 52.9M | 65.4M | 71.1M | 71.9M |
Every figure is extracted from Zentalis Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.